Loading patent…
AssigneesFred Hutchinson Cancer Research Center, Novartis Institute for Functional Genomics, Inc., Dba the Genomics Institute of the Norvatis, Research Foundation (Gnf)
InventorsIrwin D. Bernstein, Anthony E. Boitano, Michael Cooke
Estimating the term…
The present invention relates to methods, kits and compositions for expansion of hematopoietic stem/progenitor cells and providing hematopoietic function to human patients in need thereof. In one aspect, it relates to kits and compositions comprising a Notch agonist and an aryl hydrocarbon receptor antagonist. Also provided herein are methods for expanding the hematopoietic stem/progenitor cells using kits and compositions comprising a Notch agonist and an aryl hydrocarbon receptor antagonist. The hematopoietic stem/progenitor cells expanded using the disclosed kits, compositions and methods include human umbilical cord blood stem/progenitor cells, placental cord blood stem/progenitor cells and peripheral blood stem cells. The present invention also relates to administering hematopoietic stem/progenitor cells expanded using a combination of a Notch agonist and an aryl hydrocarbon receptor antagonist to a patient for short-term and/or long-term in vivo repopulation benefits.
A method of expanding hematopoietic stem/progenitor cells, comprising culturing isolated hematopoietic stem/progenitor cells ex vivo in the presence of a composition comprising a Notch agonist and an aryl hydrocarbon receptor antagonist, thereby producing an expanded hematopoietic stem/progenitor cell sample.
A method of expanding human hematopoietic stem/progenitor cells, comprising culturing isolated hematopoietic stem/progenitor cells ex vivo on a solid phase coated with Delta1ext-IgG and CH-296, and in the presence of a medium comprising an aryl hydrocarbon receptor antagonist and four or more growth factors;
A kit comprising, in one or more containers:
A solid phase comprising a surface on which a Notch agonist is immobilized, said solid phase being in contact with hematopoietic stem/progenitor cells, said cells being in contact with a fluid medium comprising an aryl hydrocarbon receptor antagonist.
Dependencies are inferred from the claim text.